News and Announcements
Cellmid FY16 Update: Strong Revenue Growth, Full Range Launched, Presence Built in Major Markets
- Published July 12, 2016 5:30PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Cellmid, a life sciences accelerator, continued to build its consumer health business during FY2016 and is on track to deliver strong revenue growth for the period.
The Company launched its full range of clinically validated hair growth products, evolis®, in Australian pharmacies in May 2015, and doubled its Japanese distribution.
Most recently, Cellmid launched an evolis® Professional range for the hair salon market, opening up major opportunities in anti-aging hair care.
With its category leading product, Cellmid started to build presence in major markets (USA, China) in 2016, planning commercial launches in the next 12 to 18 months in these regions.
ABOUT CELLMID LTD
Cellmid (ASX: CDY) develops innovative therapies and diagnostics for cancer, inflammation and heart attack. CDY has the largest global IP portfolio related to growth factor midkine (MK). Its most advanced program is for MK antibodies targeting cancer/inflammation. CDY is also developing MK protein to treat heart attack and other ischemia. CDY’s first product is a blood test measuring serum MK. MK is a powerful biomarker of early cancer. CDY’s subsidiary Advangen develops and sells scientifically validated products to prevent and treat hair loss with products that have a well understood, safe and novel mechanism (inhibiting FGF-5). Two product ranges are on market, for pharmacies (évolis®) and professional hair salons (Jo-Ju® & Lexilis®).
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
